Patents by Inventor Akira Nozawa

Akira Nozawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10285628
    Abstract: A method and a device with which an ambulatory status, including movements of an upper body, can be detected easily, without a complex operation of the equipment used, in a medical facility for rehabilitation or the like. In case of detecting the ambulatory status of a subject, the problem is solved by detecting the ambulatory status of the subject by measuring conditions of movement in at least two places, specifically, a lumber area and a thoracodorsal area of the subject.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 14, 2019
    Assignees: MICROSTONE CORPORATION
    Inventors: Akira Ichikawa, Norihiko Shiratori, Shigeya Okada, Hidetaka Nozawa
  • Publication number: 20170071911
    Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) N-methyl-2-pyrrolidone.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 16, 2017
    Inventors: Hirokazu Kobayashi, Akira Nozawa, Katsumasa Ariyoshi
  • Patent number: 9344266
    Abstract: A transmission system includes: a first transmission apparatus to distribute a synchronization clock; and one or more second transmission apparatuses each to connect to the first transmission apparatus so as to synchronize with the synchronization clock from the first transmission apparatus, the second transmission apparatus including: a selection portion to select the first or second transmission apparatus of a connection destination so as to switch the synchronization clock; an output portion to generate an inquiry signal addressed to the first transmission apparatus via the second transmission apparatus of the connection destination selected; a determination portion to determine whether or not the inquiry signal generated by the second transmission apparatus is received; and a second control portion to determine that there is a synchronization clock loop having a loop path through the second transmission apparatus of the connection destination when the determination portion receives the inquiry signal.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 17, 2016
    Assignee: FUJITSU LIMITED
    Inventors: Ryuji Kayama, Hiroyuki Suzuki, Takashi Nakano, Nobuyuki Kobayashi, Akira Nozawa, Koji Suda
  • Publication number: 20150280897
    Abstract: A transmission system includes: a first transmission apparatus to distribute a synchronization clock; and one or more second transmission apparatuses each to connect to the first transmission apparatus so as to synchronize with the synchronization clock from the first transmission apparatus, the second transmission apparatus including: a selection portion to select the first or second transmission apparatus of a connection destination so as to switch the synchronization clock; an output portion to generate an inquiry signal addressed to the first transmission apparatus via the second transmission apparatus of the connection destination selected; a determination portion to determine whether or not the inquiry signal generated by the second transmission apparatus is received; and a second control portion to determine that there is a synchronization clock loop having a loop path through the second transmission apparatus of the connection destination when the determination portion receives the inquiry signal.
    Type: Application
    Filed: February 4, 2015
    Publication date: October 1, 2015
    Applicant: FUJITSU LIMITED
    Inventors: RYUJI KAYAMA, HIROYUKI SUZUKI, TAKASHI NAKANO, Nobuyuki Kobayashi, AKIRA NOZAWA, Koji Suda
  • Patent number: 8741941
    Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: June 3, 2014
    Assignee: Pola Pharma Inc.
    Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
  • Patent number: 8349882
    Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: January 8, 2013
    Assignees: Nihon Nohyaku Co., Ltd., Pola Pharma Inc.
    Inventors: Hirokazu Kobayashi, Akira Nozawa, Katsumasa Ariyoshi
  • Patent number: 8268876
    Abstract: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) ?-hydroxycarboxylic acid and/or a salt thereof.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: September 18, 2012
    Assignees: Nihon Nohyaku Co., Ltd., Pola Pharma Inc.
    Inventors: Toyohiko Miki, Akira Nozawa, Nobuo Kubota, Susumu Tomiyama, Hirokazu Kobayashi
  • Publication number: 20120015997
    Abstract: Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 19, 2012
    Applicants: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.
    Inventors: Toyohiko Miki, Hiroyuki Fujii, Akira Nozawa, Hirokazu Kobayashi
  • Publication number: 20120015996
    Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 19, 2012
    Applicant: Pola Pharma Inc.
    Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
  • Patent number: 8058303
    Abstract: Provided is a pharmaceutical composition for external use which includes the following components: 1) luliconazole and/or a salt thereof; 2) N-methyl-2-pyrollidone; and 3) benzyl alcohol and/or diester of a dibasic acid. The diester of the dibasic acid is a diethyl ester or a diisopropyl ester of a dibasic acid having 6-10 carbon atoms. The pharmaceutical composition is useful for the treatment of a mycotic disease such as foot trichophytosis, trichophytosis corporis, trichophytosis on a hard keratin or hyperkeratotic portion, onychomycosis, particularly on a nail, or dermatomycosis.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: November 15, 2011
    Assignees: Nihon Nohyaku Co, Ltd, Pola Pharma Inc
    Inventors: Toyohiko Miki, Hiroyuki Fujii, Akira Nozawa, Hirokazu Kobayashi
  • Patent number: 8039452
    Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: October 18, 2011
    Assignee: Pola Pharma Inc.
    Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
  • Patent number: 7666678
    Abstract: The present invention provides genes and proteins having possibilities to generate plants having tolerance against excessive boron, which can confer a boric acid tolerance to organisms. 5 types of genes that can confer a boric acid tolerance to yeast, such as AtPAB2, AtRBP47c?, AtRPS20B, AtMYB13 and AtMYB68, AtRBP45a, AtRBP45b, AtRBP45c, AtRBP45d, AtRBP47a, AtRBP47b, AtRBP47c, AtUBP1a, AtUBP1b and AtUBP1c which were found by expressing several genes of higher plant Arabidopsis thaliana in yeast that is a organism model of eukaryote. Further, a key to the toxicity mechanism of boric acid exists in the specific inhibition of splicing, and a gene related to enhancement of splicing efficiency also confers a boric acid tolerance.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: February 23, 2010
    Assignee: Japan Science and Technology Agency
    Inventors: Toru Fujiwara, Akira Nozawa
  • Patent number: 7660308
    Abstract: A transmission apparatus that does not include a plurality of switches, that cross-connects a signal, and that can handle various redundancy settings determined by a user. An address information generation section generates address information indicative of the destination of a signal, from redundancy setting information and cross connect setting information. An activation information setting section activates and deactivates activation information included in the address information when failure occurs. An address information insertion section inserts the address information stored in an address information storage section into the signal and outputs the signal to a bus. A signal output section receives the signal having the address information that is the same as own address information and outputs the signal to a next stage in the case of the activation information indicating activation.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: February 9, 2010
    Assignee: Fujitsu Limited
    Inventors: Kenichi Hasegawa, Akira Nozawa, Minoru Tateno, Kenichi Miyama
  • Publication number: 20090137651
    Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
    Type: Application
    Filed: October 2, 2006
    Publication date: May 28, 2009
    Inventors: Hirokazu Kobayashi, Akira Nozawa, Katsumasa Ariyoshi
  • Publication number: 20090076109
    Abstract: Provided is a pharmaceutical composition for external use, including: (i) a compound represented by the general structural formula (1) and/or a salt thereof; and (ii) N-methyl-2-pyrolidone: Where, X represents a hydrogen atom or a chlorine atom.
    Type: Application
    Filed: October 2, 2006
    Publication date: March 19, 2009
    Applicants: NIHON NOHYAKU CO., LTD., POLA PHARMA INC.
    Inventors: Toyohiko Miki, Hiroyuki Fujii, Akira Nozawa, Hirokazu Kobayashi
  • Publication number: 20090030059
    Abstract: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) ?-hydroxycarboxylic acid and/or a salt thereof.
    Type: Application
    Filed: October 2, 2006
    Publication date: January 29, 2009
    Applicants: Nihon Nohyaku Co., Ltd., Pola Pharma Inc.
    Inventors: Toyohiko Miki, Akira Nozawa, Nobuo Kubota, Susumu Tomiyama, Hirokazu Kobayashi
  • Publication number: 20080002706
    Abstract: A transmission apparatus that does not include a plurality of switches, that cross-connects a signal, and that can handle various redundancy settings determined by a user. An address information generation section generates address information indicative of the destination of a signal, from redundancy setting information and cross connect setting information. An activation information setting section activates and deactivates activation information included in the address information when failure occurs. An address information insertion section inserts the address information stored in an address information storage section into the signal and outputs the signal to a bus. A signal output section receives the signal having the address information that is the same as own address information and outputs the signal to a next stage in the case of the activation information indicating activation.
    Type: Application
    Filed: October 19, 2006
    Publication date: January 3, 2008
    Applicant: FUJITSU LIMITED
    Inventors: Kenichi Hasegawa, Akira Nozawa, Minoru Tateno, Kenichi Miyama
  • Publication number: 20070079394
    Abstract: The present invention provides genes and proteins having possibilities to generate plants having tolerance against excessive boron, which can confer a boric acid tolerance to organisms. 5 types of genes that can confer a boric acid tolerance to yeast, such as AtPAB2, AtRBP47c?, AtRPS20B, AtMYB13 and AtMYB68, AtRBP45a, AtRBP45b, AtRBP45c, AtRBP45d, AtRBP47a, AtRBP47b, AtRBP47c, AtUBP1a, AtUBP1b and AtUBP1c which were found by expressing several genes of higher plant Arabidopsis thaliana in yeast that is a organism model of eukaryote. Further, a key to the toxicity mechanism of boric acid exists in the specific inhibition of splicing, and a gene related to enhancement of splicing efficiency also confers a boric acid tolerance.
    Type: Application
    Filed: September 15, 2006
    Publication date: April 5, 2007
    Inventors: Toru Fujiwara, Akira Nozawa
  • Patent number: 7052866
    Abstract: A correct viable cell number of a microorganism in a biological tissue is measured by cultivating a fragment of the biological tissue such as skin infected with the microorganism and administered with an antimicrobial agent, in a medium containing a phospholipid, a nonionic surfactant, or both of the phospholipid and the nonionic surfactant.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: May 30, 2006
    Assignee: Pola Chemical Industries Inc.
    Inventors: Takuji Nakashima, Akira Nozawa, Takao Ito
  • Publication number: 20050250174
    Abstract: A correct viable cell number of a microorganism in a biological tissue is measured by cultivating a fragment of the biological tissue such as skin infected with the microorganism and administered with an antimicrobial agent, in a medium containing a phospholipid, a nonionic surfactant, or both of the phospholipid and the nonionic surfactant.
    Type: Application
    Filed: June 15, 2005
    Publication date: November 10, 2005
    Inventors: Takuji Nakashima, Akira Nozawa, Takao Ito